ARMS2/HTRA1 in non–cell-autonomous oxidative and anti-inflammatory therapeutic targeting.

Drs. Tsang and Olah will use CRISPR to identify the causative allele of AMD pathologies and investigate the stress signals of microglia (resident immune cells of the brain,) in AMD that might be treatable as part of a therapeutic strategy to reduce AMD-related cell death. They will also explore whether the presence of at least one low-risk ARMS2/HTRA1 allele maintains oxidative, anti-inflammatory, and overall cellular health in microglia.